GSK, Genmab fail to get NICE nod for leukemia drug

06/23/2010 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence decided not to endorse GlaxoSmithKline and Genmab's leukemia drug Arzerra, citing lack of evidence on the drug's effectiveness compared with standard treatment. GSK recently failed to gain NICE recommendation for cancer medicine Tyverb and platelet drug Revolade.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY